Found 322 articles
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed patient enrollment of a bridging study of tazemetostat in China.
MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for tulmimetostat, the company's investigational next-generation dual inhibitor of EZH2 and EZH1, for the treatment of patients with advanced, recurrent or metastatic endometrial cancer harboring AT-rich interacting domain containing protein 1A (ARID1A) mutations and who have progressed on at least one prior line of treatment.
The FDA has lifted the clinical hold it had placed on the Phase Ib study following the occurrence of hematological malignancies.
HUTCHMED Limited, the innovative, commercial-stage biopharmaceutical company, reports its unaudited financial results for the six months ended June 30, 2023 and provides updates on key clinical and commercial developments.
HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings
HUTCHMED Limited announces that new and updated clinical data related to two novel investigational hematological malignancy therapies, HMPL-306 and amdizalisib, will be presented at the upcoming European Hematology Association Annual Meeting, taking place June 8-11, 2023 in Frankfurt, and the 17th International Conference on Malignant Lymphoma taking place June 13-17, 2023 in Lugano.
Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
Bristol Myers Squibb announced first results from the Phase 3 COMMANDS study, an open-label, randomized trial evaluating Reblozyl® versus epoetin alfa, an erythropoiesis-stimulating agent, for the treatment of anemia in adult patients with very low-, low- or intermediate-risk myelodysplastic syndromes who require red blood cell transfusions and are ESA-naïve.
Evopoint Announces Clinical Trial Collaboration Agreement with MSD for the Study of XNW5004 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors
Evopoint Biosciences Co., Ltd.(“Evopoint”) announced today a collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate Evopoint’s XNW5004, a selective EZH2 inhibitor, in combination with KEYTRUDA®(pembrolizumab), MSD’s anti-PD-1 therapy, in a Phase Ib/II study in Chinese patients with advanced solid tumors.
HUTCHMED Limited reports its financial results for the year ended December 31, 2022 and provides updates on key clinical and commercial developments.
HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
HUTCHMED Limited announces that it has completed patient enrollment of Phase II registration trial of amdizalisib in patients with relapsed or refractory follicular lymphoma, a subtype of non-Hodgkin’s lymphoma.
Cellworks Biosimulation Study Reveals Biomarkers That Predict Response to Hypomethylating Agents and Patient Survival in MDS
Cellworks Group Inc. today announced results from a study that examined how Differentiation Scoring (DS) derived from key myeloid biomarkers in individual Myelodysplastic Syndrome (MDS) patients using the Cellworks Platform and Computational Biology Model (CBM) can predict response to Hypomethylating Agents (HMA).
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients
AbbVie announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2022.
Ascentage Pharma Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies
Ascentage Pharma (6855.HK) today announced that its novel inhibitor of the embryonic ectoderm development (EED) protein, APG-5918, has been approved by the Center for Drug Evaluations (CDE) of China National Medical Products Administration (NMPA) to enter a Phase I study in patients with advanced solid tumors or hematologic malignancies.
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
MorphoSys AG announced that preliminary results from the ongoing Phase 1/2 study of tulmimetostat monotherapy in heavily pretreated patients with advanced cancers showed responses or disease stabilization in five cohorts with evaluable patients.
Daiichi Sankyo won approval in Japan for Ezharmia, making it the first dual inhibitor of EZH1 and EZH2 to receive regulatory approval for ATL.
Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme).
Epizyme today reported second quarter 2022 financial results and provided a business update.
HUTCHMED Limited, the innovative, commercial-stage biopharmaceutical company, reports its unaudited financial results and provides updates on key clinical and commercial developments for the six months ended June 30, 2022.
HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
HUTCHMED Limited announces that it has initiated a bridging study of tazemetostat in China.
Ascentage Pharma Announces IND Clearance by the US FDA for First-in-Human Study of Novel EED Inhibitor APG-5918
Ascentage Pharma announced that its novel inhibitor of the embryonic ectoderm development protein, APG-5918, has been cleared by the US Food and Drug Administration to enter a first-in-human study that will assess the safety, pharmacokinetics, and preliminary efficacy of APG-5918 in patients with solid tumors or hematologic malignancies.